Liu Shenghui
Lin He's Academician Workstation of New Medicine and Clinical Translation, Jining Medical University, Jining, China.
Heliyon. 2024 Sep 2;10(17):e37265. doi: 10.1016/j.heliyon.2024.e37265. eCollection 2024 Sep 15.
The aryl hydrocarbon receptor (AHR) is a transcription factor activated by ligands that participates in many important physiological processes. Although AHR activation is associated with hepatomegaly, the underlying mechanism remains unclear. This study evaluated the effects of AHR activation on liver enlargement and regeneration in various transgenic mice and animal models. Activation of AHR by the non-toxic ligand YH439 significantly induced liver/body weight ratio in wild-type mice (1.37-fold) and AHR mice (1.54-fold). However, these effects not present in AHR mice. Additionally, the activation of AHR promotes hepatocyte enlargement (1.43-fold or 1.41-fold) around the central vein (CV) and increases number of Ki67 cells (42.5-fold or 48.8-fold) around the portal vein (PV) in wild-type mice and AHR mice. In the 70 % partial hepatectomy (PHx) model, YH439 significantly induced hepatocyte enlargement (1.40-fold) and increased number of Ki67 cells (3.97-fold) in AHR mice. However, these effects were not observed in AHR mice. Co-immunoprecipitation results suggested a potential protein-protein interaction between AHR and Yes-associated protein (YAP). Disruption of the association between YAP and transcription enhancer domain family member (TEAD) significantly inhibited AHR-induced liver enlargement and regeneration. Furthermore, AHR failed to induce liver enlargement and regeneration in YAP mice. Blocking the YAP signaling pathway effectively eliminated AHR-induced liver enlargement and regeneration. This study revealed the molecular mechanism of AHR regulation of liver size and regeneration through the activation of AHR-TEAD signaling pathway, thereby offering novel insights into the physiological role of AHR. These findings provide a theoretical foundation for the prevention and treatment of disorders associated with liver regeneration.
芳烃受体(AHR)是一种由配体激活的转录因子,参与许多重要的生理过程。尽管AHR激活与肝肿大有关,但其潜在机制仍不清楚。本研究评估了AHR激活对各种转基因小鼠和动物模型肝脏肿大及再生的影响。无毒配体YH439激活AHR可显著诱导野生型小鼠(1.37倍)和AHR小鼠(1.54倍)的肝/体重比升高。然而,这些效应在AHR缺陷小鼠中不存在。此外,AHR激活可促进野生型小鼠和AHR缺陷小鼠中央静脉(CV)周围的肝细胞肿大(1.43倍或1.41倍),并增加门静脉(PV)周围的Ki67细胞数量(42.5倍或48.8倍)。在70%部分肝切除术(PHx)模型中,YH439可显著诱导AHR缺陷小鼠的肝细胞肿大(1.40倍)并增加Ki67细胞数量(3.97倍)。然而,在AHR缺陷小鼠中未观察到这些效应。免疫共沉淀结果提示AHR与Yes相关蛋白(YAP)之间可能存在蛋白质-蛋白质相互作用。YAP与转录增强子结构域家族成员(TEAD)之间的结合破坏显著抑制了AHR诱导的肝脏肿大和再生。此外,AHR在YAP缺陷小鼠中未能诱导肝脏肿大和再生。阻断YAP信号通路可有效消除AHR诱导的肝脏肿大和再生。本研究揭示了AHR通过激活AHR-TEAD信号通路调节肝脏大小和再生的分子机制,从而为AHR的生理作用提供了新的见解。这些发现为预防和治疗与肝脏再生相关的疾病提供了理论基础。